Rafael Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rafael Holdings, Inc. (the "Company") on January 22, 2021. The report details a corporate transaction involving the Company's 90%-owned subsidiary, Pharma Holdings, LLC, and its investment in Rafael Pharmaceuticals, Inc.
Key Financial Metrics and Transaction Details
- Transaction Type: Partial exercise of a warrant to purchase Series D Convertible Preferred Stock of Rafael Pharmaceuticals, Inc.
- Shares Purchased: 7,298,950 shares.
- Total Exercise Price: $9,123,687.50.
- Company Funding: The Company funded 90% of the aggregate exercise price, commensurate with its ownership interest in the subsidiary.
- Warrant Capacity: The warrant is exercisable for up to 56.0% of Rafael Pharmaceuticals' equity.
Material Changes and Ownership Position
Following the exercise, the Company and its subsidiaries collectively own:
- 51.0% of the outstanding capital stock of Rafael Pharmaceuticals.
- 41.1% of the capital stock on a fully diluted basis (excluding the remainder of the Warrant).
This transaction was executed to maintain the Company's majority ownership of outstanding capital stock and increase its fully diluted position following equity issuances to third-party stockholders.
Outlook, Risks, and Contingencies
The filing highlights several risks regarding future capital structure and funding requirements:
- Dilution Risk: Rafael Pharmaceuticals may issue additional equity interests, which could require the Company to further exercise the Warrant to maintain ownership percentages.
- Cost Increase: Additional issuances would increase the total cost required to exercise the Warrant in full.
- Potential Issuances: Future equity issuances could include employee stock options, "Bonus Shares" (up to 10% of fully diluted capital stock upon milestone satisfaction), and shares under a line of credit agreement (representing 12% of issued and outstanding shares).
Investor Verification Checklist
- Verify the current fully diluted ownership percentage of Rafael Holdings in Rafael Pharmaceuticals.
- Confirm the remaining unexercised portion of the Warrant and the associated potential capital outlay.
- Review the terms of the line of credit agreement and the specific milestones required for "Bonus Shares" issuance.
- Assess the liquidity impact of the $9.1 million expenditure on the Company's cash position.